373 related articles for article (PubMed ID: 22808292)
1. ALK-immunoreactive neoplasms.
Minoo P; Wang HY
Int J Clin Exp Pathol; 2012; 5(5):397-410. PubMed ID: 22808292
[TBL] [Abstract][Full Text] [Related]
2. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
3. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
4. ALK-positive anaplastic large cell lymphoma: an evolving story.
Bonzheim I; Steinhilber J; Fend F; Lamant L; Quintanilla-Martinez L
Front Biosci (Schol Ed); 2015 Jun; 7(2):248-59. PubMed ID: 25961700
[TBL] [Abstract][Full Text] [Related]
5. Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer.
Dagogo-Jack I; Shaw AT; Riely GJ
Clin Pharmacol Ther; 2017 May; 101(5):625-633. PubMed ID: 28182271
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
Eyre TA; Khan D; Hall GW; Collins GP
Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
[TBL] [Abstract][Full Text] [Related]
7. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
8. The anaplastic lymphoma kinase as an oncogene in solid tumors.
Voena C; Peola S; Chiarle R
Front Biosci (Schol Ed); 2015 Jun; 7(2):269-82. PubMed ID: 25961702
[TBL] [Abstract][Full Text] [Related]
9. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
10. Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.
Takeoka K; Okumura A; Honjo G; Ohno H
J Clin Exp Hematop; 2014; 54(3):225-35. PubMed ID: 25501114
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
Katayama R; Lovly CM; Shaw AT
Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
[TBL] [Abstract][Full Text] [Related]
13. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
[TBL] [Abstract][Full Text] [Related]
14. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines.
Carnesecchi S; Rougemont AL; Doroshow JH; Nagy M; Mouche S; Gumy-Pause F; Szanto I
Free Radic Biol Med; 2015 Jul; 84():22-29. PubMed ID: 25797883
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
16. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
17. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
18. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
19. Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult.
Wang CX; Wang H; Li J; Ma HH; Yu B; Shi SS; Zhou XJ; Shi QL
Int J Clin Exp Pathol; 2014; 7(3):1182-7. PubMed ID: 24696735
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase: Role in cancer and therapy perspective.
Zhao Z; Verma V; Zhang M
Cancer Biol Ther; 2015; 16(12):1691-701. PubMed ID: 26529396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
